Patents by Inventor Tricia J. Vos

Tricia J. Vos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryls and uses thereof
    Patent number: 8796314
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, CY, X1, X2, and X3 are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: August 5, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Zhan Shi, Irache Visiers, Tricia J. Vos, Stepan Vyskocil
  • THIOLACTAMS AND USES THEREOF
    Publication number: 20140194410
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: November 7, 2013
    Publication date: July 10, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Matthew O. Duffey, Amy M. Elder, Jianping Guo, Gang Li, Dominic Reynolds, Francois Soucy, Tricia J. Vos
  • Thiolactams and uses thereof
    Patent number: 8507667
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: August 13, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Matthew O. Duffey, Amy M. Elder, Jianping Guo, Gang Li, Dominic Reynolds, Francois Soucy, Tricia J. Vos
  • Compounds and methods for inhibiting mitotic progression
    Patent number: 8399659
    Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: March 19, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christoper F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
  • THIOLACTAMS AND USES THEREOF
    Publication number: 20120309743
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: August 9, 2012
    Publication date: December 6, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Matthew Duffey, Amy Elder, Jianping Guo, Gang Li, Dominic Reynolds, Francois Soucy, Tricia J. Vos
  • THIOLACTAMS AND USES THEREOF
    Publication number: 20120302551
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: August 9, 2012
    Publication date: November 29, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Matthew Duffey, Amy Elder, Jianping Guo, Gang Li, Dominic Reynolds, Francois Soucy, Tricia J. Vos
  • Thiolactams and uses thereof
    Patent number: 8268992
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: September 18, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Matthew Duffey, Amy Elder, Jianping Guo, Gang Li, Dominic Reynolds, Francois Soucy, Tricia J. Vos
  • HETEROARYLS AND USES THEREOF
    Publication number: 20120142732
    Abstract: This invention provides compounds of formula IA or IB: wherein HY, R1, R2, and G1, are as described in the specification. The compounds are inhibitors of VPS34 and/or PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: August 10, 2011
    Publication date: June 7, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Courtney A. Cullis, Krista E. Granger, Jianping Guo, Masaaki Hirose, Gang Li, Miho Mizutani, Tricia J. Vos
  • Bicyclic compounds with kinase inhibitory activity
    Patent number: 8110687
    Abstract: The present invention provides novel bicyclic compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: February 7, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Emily F. Calderwood, Alexandra E. Gould, Paul D. Greenspan, Robyn Scott Rowland, Tricia J. Vos, Matthew J. LaMarche
  • THIOLACTAMS AND USES THEREOF
    Publication number: 20110257157
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: June 30, 2011
    Publication date: October 20, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Matthew Duffey, Amy Elder, Jianping Guo, Gang Li, Dominic Reynolds, Francois Soucy, Tricia J. Vos
  • Thiolactams and uses thereof
    Patent number: 7998952
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: August 16, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Matthew Duffey, Amy Elder, Jianping Guo, Gang Li, Dominic Reynolds, Francois Soucy, Tricia J. Vos
  • Heteroaryls and uses thereof
    Publication number: 20100256172
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, CY, X1, X2, and X3 are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: January 28, 2010
    Publication date: October 7, 2010
    Applicants: Millennium Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited
    Inventors: Zhan Shi, Irache Visiers, Tricia J. Vos, Stepan Vyskocil
  • Certain pyrazoline derivatives with kinase inhibitory activity
    Patent number: 7795249
    Abstract: The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: September 14, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ruth S. Adams, Matthew Duffey, Alexandra E. Gould, Paul D. Greenspan, Bheemashankar A. Kulkarni, Tricia J. Vos
  • Modulators of melanocortin receptor
    Patent number: 7790719
    Abstract: This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses. The compounds are represented by formula I: wherein X is oxygen or sulfur; G is G1 or G2: L1, L2, L3 and Q are linker groups, and Rings A, B and C, and R1-R14 are described in the specification. The compounds are antagonists of melanocortin receptors.
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: September 7, 2010
    Assignee: Ore Pharmaceuticals, Inc.
    Inventors: Tricia J. Vos, Michael Patane, Michael E. Solomon, Christopher Blackburn, Mihaela D. Danca
  • THIOLACTAMS AND USES THEREOF
    Publication number: 20100179126
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: December 4, 2009
    Publication date: July 15, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Matthew Duffey, Amy Elder, Jianping Guo, Gang Li, Dominic Reynolds, Francois Soucy, Tricia J. Vos
  • Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
    Patent number: 7652041
    Abstract: The present invention provides novel cinnamide compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: January 26, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ruth S. Adams, Emily F. Calderwood, Alexandra E. Gould, Paul D. Greenspan, Matthew J LaMarche, Yuan Tian, Tricia J. Vos
  • Thiophenes and uses thereof
    Publication number: 20090325925
    Abstract: This invention provides thiophene compounds of formula I: wherein R1, R2, R3, R4, n, p, and m are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: January 26, 2009
    Publication date: December 31, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christelle C. Renou, Tricia J. Vos, Matthew O. Duffey, Robert Downham
  • COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION
    Publication number: 20090299060
    Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Application
    Filed: May 27, 2009
    Publication date: December 3, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
  • Compounds and methods for inhibiting mitotic progression
    Patent number: 7572784
    Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: August 11, 2009
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
  • Melanocortin-4 receptor binding compounds and methods of use thereof
    Publication number: 20080269217
    Abstract: Provided are MC4-R binding compounds of the formula XVII: wherein L2 is a linker group, and P1, P2, P3, P4, Z1, Z2, Z3, Z4, Z5, t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.
    Type: Application
    Filed: May 1, 2008
    Publication date: October 30, 2008
    Applicant: Ore Pharmaceuticals, Inc.
    Inventors: Tricia J. Vos, Michael E. Solomon, Christopher F. Claiborne, Martin P. Maguire, Mingshi Dai, Michael Patane, Thoma H. Marsilje